Clinical Trials Directory

We are doing this study to examine genetic changes in your tumor that may contribute to resistance to immunotherapy. With this information, we hope to be able to identify new treatment methods as well as improve our ability to identify patients more likely to respond to immunotherapy.

We are doing this study to find out if an experimental drug called felzartamab (the study drug) is a safe and effective option for people who have had a kidney transplant and are experiencing antibody-mediated rejection (AMR). We want to know if this drug provides any helpful benefit.

We are doing this study to find out if an experimental drug called LY4337713 (the study drug) is a safe and effective option for people who have FAP-positive solid tumors. The study drug is a type of radiotherapy that is intended to target and attach only to FAP. The goal of targeted radiotherapy is to provide selective delivery of radiation doses that can destroy tumor cells.

This study has three parts. First is the screening phase, where doctors check if a person can join. Next is the treatment phase, where the person gets the study medicine and has an End of Treatment visit. Last is the long-term follow-up, where doctors watch the person’s health for a long time. This includes a safety check 30 days after treatment. A person may be in the study for up to 5 years. There are two groups in the study. People will be placed into a group by chance. One group will get the study medicine, and the other group will get chemotherapy chosen by the doctor. The study medicine is called Tovorafenib. It is used to treat certain brain tumors in children and young adults, especially a type called pediatric low-grade gliomas that have changes in the RAF or BRAF gene.

This study is for people with a kind of brain cancer called GBM. They will be placed into one of two treatment groups—either a regular treatment or a new one being tested. The study has two parts. In the first part, doctors choose treatments based on how well they are working for others with similar cancer. In the second part, treatments that look helpful are tested more closely. People in the study will have brain scans every 6 to 8 weeks to check the size of the tumor. They will also have blood tests, physical check-ups, and answer questions about how they feel. Some people may take tests to check their thinking and memory. Treatment will continue until the cancer gets worse or the side effects become too strong. Regular treatments include radiation and a medicine called temozolomide for people who are newly diagnosed. For people whose cancer has come back, the treatment is a chemotherapy medicine called lomustine.

We are doing this study to find the most effective, safe dose of an experimental drug called CTL-002 (the study drug) when it is given in combination with nivolumab and docetaxel for patients who have metastatic non-squamous non-small cell lung cancer (NSCLC).

We are doing this study to understand more about biomarkers (a part of your body) and how they can be used to better diagnose infection. To learn more, please contact us at DukeMESSIStudy@Duke.edu or at 919-452-1605. Estamos haciendo este estudio para entender más sobre biomarcadores (que son parte de su cuerpo) y cómo pueden ser usados estos para diagnosticar infecciones de una mejor manera. Para mayor información, por favor contáctenos al correo DukeMESSIStudy@Duke.edu o al número 919-452-1605.

We are doing this study to learn more about the cause of cardiac (heart) disease or sudden unexplained death, which is something that can run in families. Some conditions that we are looking at are:

• Cardiomyopathies (a disease of the heart muscle that makes it harder for your heart to pump blood to the rest of your body) like hypertrophic cardiomyopathy, dilated cardiomyopathy, or arrhythmogenic cardiomyopathy (also called right ventricular cardiomyopathy)
• Arrhythmia syndromes (a problem with the rate or rhythm of the heartbeat, either too slow or too fast) like long QT syndrome, Brugada syndrome, catecholaminergic polymorphic ventricular tachycardia, or short QT syndrome
• Sudden cardiac arrest or unexplained sudden death (heart stops suddenly) in someone less than 50 years of age, including sudden infant death syndrome (SIDS)
• Individuals with genetic mutations (variants) in genes that can lead to cardiac disease which include (LMNA, ATP1A3, and TAX1BP3)